Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
about
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsPseudomonas aeruginosa ventilator-associated pneumonia managementCeftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationCeftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsPharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypesImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolatesWill new antimicrobials overcome resistance among Gram-negatives?Providing β-lactams a helping hand: targeting the AmpC β-lactamase induction pathway.Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.New antibiotics for bad bugs: where are we?Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth.Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing.Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain.In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance MechanismsN-acetylcysteine selectively antagonizes the activity of imipenem in Pseudomonas aeruginosa by an OprD-mediated mechanism.Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania.Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpCMutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.
P2860
Q26747429-67E81181-CFDD-4CD2-A18E-42DC99B3A2B2Q26768365-48D93847-F336-450E-9A1E-4729C5E53523Q26998883-D68C7924-74D6-4891-85E9-E753CD699FE1Q28069563-E790B648-5759-4503-B5EB-BC0722A1855AQ34045418-9AF9F0D9-82AD-4B6B-A610-3B524707D5ACQ34057425-5784E42A-E832-47C5-B96B-08856D20B409Q34164594-B5A9E087-150E-46D8-A604-BFF9F8C3FE96Q34299064-39A01E25-A7A3-441D-BFCC-610A17E82C8EQ34320027-AD88894E-C60A-4953-8337-935321F9796BQ34393008-AD88B068-7C8A-43A6-882B-2E52438CAC3BQ34933120-1E2EAEA2-BDE6-4CB8-9406-D3B8342A8B75Q35666617-7523277F-389B-440A-9B9B-26B0A990208FQ36018548-733BF627-5C2D-432C-B0B7-DDED926B97D0Q36075893-6EBDB5C4-73EC-4040-BB3D-80849FF60065Q36172484-5935DC85-345D-4219-9D70-0BC6FAB4B514Q36730017-A3798D88-A407-4833-8071-B835A603E9F2Q37263317-63ADC0A3-E106-44D2-8B6A-F0D4CD6EA285Q37317645-1F8610BA-7F23-4F79-B7A3-E07AD795AA08Q37335781-8919C305-2599-44EF-B88F-5253EBB1BBF9Q37544754-C54616DF-2CD5-424A-B374-920E151826B0Q37942654-2EAA1BDC-39AA-4626-B8B4-3A07DB30E18CQ37961906-098BEF38-494B-4BBA-8944-7F8F28D7528FQ38115356-386A56EA-7875-4C78-935C-1D41030BD9C8Q38132217-58B5E1E8-75EB-420E-874E-01114F26A0F5Q38241417-BB910B3B-3482-4C5C-9F36-2BF6C59DDFF2Q38541624-EAE1CAF4-C246-4210-A2B5-37E8C5AE4007Q38626934-CAAB15CA-4E62-495D-83FB-C7BA5ACF91B3Q39037981-C6FC84F2-076C-47D7-B0DD-B8994AAC3912Q39683346-620B598D-3939-408D-A4A4-15E40AF8ADA8Q40056971-FD318851-E1CB-490E-9124-A286B8D47401Q40148490-97F05BF3-341C-482E-B12A-97295BCFD044Q40296000-8B563961-07C1-4A3E-BECC-58AFF8190B88Q40401367-F02BF0E3-A04E-4D40-B613-9D07D6AC4548Q40592595-A49383E4-33ED-41AC-9541-4F6C76D361EDQ40677243-2EB81C65-1283-44FB-BE67-C27607577635Q40882363-391DE71C-C48C-4339-AC3D-AC226D25EDCBQ41075944-DC067D93-F8D3-4C3C-A9A4-61BFD83C58D0Q41757275-4D4EC336-9587-419F-A141-7F787534F6B3Q42430254-FAEEBC2A-6554-454E-8176-B16BADA29373Q44053339-3AE41A76-6B4C-413E-B7F5-C91456EC9468
P2860
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Activity of a new cephalospori ...... intensive care unit patients.
@en
type
label
Activity of a new cephalospori ...... intensive care unit patients.
@en
prefLabel
Activity of a new cephalospori ...... intensive care unit patients.
@en
P2093
P2860
P356
P1476
Activity of a new cephalospori ...... intensive care unit patients.
@en
P2093
Antonio Oliver
Bartolome Moya
José L Pérez
Laura Zamorano
P2860
P304
P356
10.1128/AAC.01104-09
P407
P50
P577
2010-01-19T00:00:00Z